Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings (Q34572539)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

title

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

main subject

patient

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

chemotherapy

1 reference

based on heuristic

inferred from title

author name string

Lorenzo Cohen

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

Carl A de Moor

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

Peter Eisenberg

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

Eileen E Ming

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

Henry Hu

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

publication date

14 November 2006

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

published in

Supportive Care in Cancer

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

volume

15

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

page(s)

497-503

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

cites work

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00520-006-0173-Z

retrieved

21 January 2018

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00520-006-0173-Z

retrieved

21 January 2018

Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency and clinical implications of delayed nausea and delayed emesis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress in the control of acute and delayed emesis induced by cisplatin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effective control of cisplatin-induced nausea using high-dose steroids and droperidol.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NCCN antiemesis practice guidelines

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delayed Chemotherapy-Induced Nausea in Women Treated for Breast Cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treate

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17103197

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00520-006-0173-Z

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

PubMed publication ID

17103197

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17103197

retrieved

3 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34572539&oldid=2196810045"